- Home
- IKNA vs EPIX Comparison
IKNA vs EPIX Comparison
Compare IKNA & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKNA
- EPIX
- Stock Information
- Founded
- IKNA 2016
- EPIX 2009
- Country
- IKNA United States
- EPIX Canada
- Employees
- IKNA N/A
- EPIX N/A
- Industry
- IKNA Biotechnology: Pharmaceutical Preparations
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- IKNA Health Care
- EPIX Health Care
- Exchange
- IKNA Nasdaq
- EPIX Nasdaq
- Market Cap
- IKNA 61.8M
- EPIX 65.3M
- IPO Year
- IKNA 2021
- EPIX N/A
- Fundamental
- Price
- IKNA $1.11
- EPIX $1.79
- Analyst Decision
- IKNA Buy
- EPIX Hold
- Analyst Count
- IKNA 2
- EPIX 3
- Target Price
- IKNA $3.00
- EPIX $2.00
- AVG Volume (30 Days)
- IKNA 84.2K
- EPIX 186.2K
- Earning Date
- IKNA 05-12-2025
- EPIX 05-13-2025
- Dividend Yield
- IKNA N/A
- EPIX N/A
- EPS Growth
- IKNA N/A
- EPIX N/A
- EPS
- IKNA N/A
- EPIX N/A
- Revenue
- IKNA N/A
- EPIX N/A
- Revenue This Year
- IKNA N/A
- EPIX N/A
- Revenue Next Year
- IKNA N/A
- EPIX N/A
- P/E Ratio
- IKNA N/A
- EPIX N/A
- Revenue Growth
- IKNA N/A
- EPIX N/A
- 52 Week Low
- IKNA $0.97
- EPIX $1.40
- 52 Week High
- IKNA $1.94
- EPIX $7.88
- Technical
- Relative Strength Index (RSI)
- IKNA 38.47
- EPIX 69.44
- Support Level
- IKNA $1.06
- EPIX $1.42
- Resistance Level
- IKNA $1.25
- EPIX $1.88
- Average True Range (ATR)
- IKNA 0.10
- EPIX 0.10
- MACD
- IKNA 0.00
- EPIX 0.03
- Stochastic Oscillator
- IKNA 39.83
- EPIX 81.32
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.